Immune enhancement in mice by ara-A.
Ara-A in single, apparently nontoxic doses stimulates murine immune responses to several well-defined antigens. Both humoral and cell-mediated responses are enhanced by ara-A, but not all mouse strains respond equally well. In certain mouse strains, ara-A also promotes increased (or decreased) survival during experimental infection with Cryptococcus neoformans, suggesting that clinically significant effects on host resistance may result from the use of ara-A as an antiviral therapeutic agent. The biochemical mechanisms of action of the aranucleosides suggest that the immunostimulation produced by ara-A depends on suppressor cell toxicity.
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000921:Antibody-Producing Cells / Q000276:immunology; D003453:Cryptococcosis / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D005260:Female; D006462:Hemolytic Plaque Technique; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000188:drug therapy / Q000276:immunology; D051379:Mice; D008805:Mice, Inbred A; D008806:Mice, Inbred AKR; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D014301:Trinitrobenzenes / Q000276:immunology; D014740:Vidarabine / Q000494:pharmacology* / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D014301:Trinitrobenzenes; D014740:Vidarabine